Sign in
4

Changes in Ownership

Cullinan Therapeutics, Inc. Filed Acc 0000899243-21-002076

Director bought 300,000 shares at $21.00 ($6,300,000)

  • Director acquired 7,613,887 shares (conversion)
  • Director acquired 281,268 shares (other)

From the SEC's structured data for this filing

Trades in this filing

Table I: Non-derivative

Insider Date Transaction Shares Price Value Owned after D/I
GADICKE ANSBERT Director 2021-01-07 Other acquisition +281,268 281,268 D: show line 1 in the form
GADICKE ANSBERT Director 2021-01-12 Conversion +1,136,525 1,136,525 I: show line 2 in the form
GADICKE ANSBERT Director 2021-01-12 Conversion +3,551,640 4,688,165 I: show line 3 in the form
GADICKE ANSBERT Director 2021-01-12 Conversion +2,276,692 6,964,857 I: show line 4 in the form
GADICKE ANSBERT Director 2021-01-12 Conversion +649,030 7,613,887 I: show line 5 in the form
GADICKE ANSBERT Director 2021-01-12 Purchase +300,000 $21.00 $6,300,000 7,913,887 I: show line 6 in the form
Open-market purchases · 300,000 sh · avg $21.00 · $6,300,000

Table II: Derivative

Insider Date Transaction Shares Price Value Exercise Expires Underlying Owned after D/I
GADICKE ANSBERT Director 2021-01-07 Other acquisition · Series Seed Convertible Preferred Stock +1,136,525 1,136,525 I: show line 7 in the form
GADICKE ANSBERT Director 2021-01-07 Other acquisition · Series A Convertible Preferred Stock +3,551,640 3,551,640 I: show line 8 in the form
GADICKE ANSBERT Director 2021-01-07 Other acquisition · Series B Convertible Preferred Stock +2,276,692 2,276,692 I: show line 9 in the form
GADICKE ANSBERT Director 2021-01-07 Other acquisition · Series C Convertible Preferred Stock +649,030 649,030 I: show line 10 in the form
GADICKE ANSBERT Director 2021-01-07 Other acquisition · Stock Option (Right to Buy) +262,114 262,114 D: show line 11 in the form
GADICKE ANSBERT Director 2021-01-07 Other acquisition · Stock Option (Right to Buy) +88,824 88,824 D: show line 12 in the form
GADICKE ANSBERT Director 2021-01-12 Conversion · Series Seed Convertible Preferred Stock −1,136,525 0 I: show line 13 in the form
GADICKE ANSBERT Director 2021-01-12 Conversion · Series A Convertible Preferred Stock −3,551,640 0 I: show line 14 in the form
GADICKE ANSBERT Director 2021-01-12 Conversion · Series B Convertible Preferred Stock −2,276,692 0 I: show line 15 in the form
GADICKE ANSBERT Director 2021-01-12 Conversion · Series C Convertible Preferred Stock −649,030 0 I: show line 16 in the form
Loading xslF345X03/doc4.xml…